List of Zepatier drug patents
Zepatier is owned by Merck Sharp Dohme.
Zepatier contains Elbasvir; Grazoprevir.
Zepatier has a total of 2 drug patents out of which 0 drug patents have expired.
Zepatier was authorised for market use on 28 January, 2016.
Zepatier is available in tablet;oral dosage forms.
Zepatier can be used as treatment of patients infected with hepatitis c virus.
The generics of Zepatier are possible to be released after 04 May, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7973040 | MERCK SHARP DOHME | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(6 years from now) | |
| US8871759 | MERCK SHARP DOHME | Inhibitors of hepatitis C virus replication |
May, 2031
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 9, 2024 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET;ORAL
ZEPATIER family patents
17
United States
4
China
4
European Union
3
Spain
3
Hong Kong
3
Denmark
3
RS
3
Poland
3
Japan
3
ME
3
Croatia
3
Korea, Republic of
3
Cyprus
3
Slovenia
3
Hungary
2
Dominican Republic
2
Malaysia
2
Brazil
2
Canada
2
Ukraine
2
Singapore
2
Morocco
2
EA
2
Norway
2
Nicaragua
2
New Zealand
2
Peru
2
Israel
2
Portugal
2
Mexico
2
Australia
2
Costa Rica
2
Ecuador
2
Netherlands
2
South Africa
2
Colombia
2
Lithuania
2
Luxembourg
2
Tunisia
1
Argentina
1
Honduras
1
Chile
1
El Salvador
1
Taiwan
1
Georgia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic